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A B S T R A C T
Background
There may be an association between periodontitis and cardiovascular disease (CVD); however, the evidence so far has been uncertain
about whether periodontal therapy can help prevent CVD in people diagnosed with chronic periodontitis. This is the second update of
a review originally published in 2014, and first updated in 2017. Although there is a new multidimensional staging and grading system
for periodontitis, we have retained the label 'chronic periodontitis' in this version of the review since available studies are based on the
previous classification system.
Objectives
To investigate the eHects of periodontal therapy for primary or secondary prevention of CVD in people with chronic periodontitis.
Search methods
Cochrane Oral Health's Information Specialist searched the Cochrane Oral Health's Trials Register, CENTRAL, MEDLINE, Embase, and
CINAHL, two trials registries, and the grey literature to September 2019. We placed no restrictions on the language or date of publication.
We also searched the Chinese BioMedical Literature Database, the China National Knowledge Infrastructure, the VIP database, and
Sciencepaper Online to August 2019.
Selection criteria
We included randomised controlled trials (RCTs) that compared active periodontal therapy to no periodontal treatment or a diHerent
periodontal treatment. We included studies of participants with a diagnosis of chronic periodontitis, either with CVD (secondary prevention
studies) or without CVD (primary prevention studies).
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Data collection and analysis
Two review authors carried out the study identification, data extraction, and 'Risk of bias' assessment independently and in duplicate.
They resolved any discrepancies by discussion, or with a third review author. We adopted a formal pilot-tested data extraction form, and
used the Cochrane tool to assess the risk of bias in the studies. We used GRADE criteria to assess the certainty of the evidence.
Main results
We included two RCTs in the review. One study focused on the primary prevention of CVD, and the other addressed secondary prevention.
We evaluated both as being at high risk of bias. Our primary outcomes of interest were death (all-cause and CVD-related) and all
cardiovascular events, measured at one-year follow-up or longer.
For primary prevention of CVD in participants with periodontitis and metabolic syndrome, one study (165 participants) provided very low-
certainty evidence. There was only one death in the study; we were unable to determine whether scaling and root planning plus amoxicillin
and metronidazole could reduce incidence of all-cause death (Peto odds ratio (OR) 7.48, 95% confidence interval (CI) 0.15 to 376.98), or all
CVD-related death (Peto OR 7.48, 95% CI 0.15 to 376.98). We could not exclude the possibility that scaling and root planning plus amoxicillin
and metronidazole could increase cardiovascular events (Peto OR 7.77, 95% CI 1.07 to 56.1) compared with supragingival scaling measured
at 12-month follow-up.
For secondary prevention of CVD, one pilot study randomised 303 participants to receive scaling and root planning plus oral hygiene
instruction (periodontal treatment) or oral hygiene instruction plus a copy of radiographs and recommendation to follow-up with a dentist
(community care). As cardiovascular events had been measured for diHerent time periods of between 6 and 25 months, and only 37
participants were available with at least one-year follow-up, we did not consider the data to be suHiciently robust for inclusion in this
review. The study did not evaluate all-cause death and all CVD-related death. We are unable to draw any conclusions about the eHects of
periodontal therapy on secondary prevention of CVD.
Authors' conclusions
For primary prevention of cardiovascular disease (CVD) in people diagnosed with periodontitis and metabolic syndrome, very low-certainty
evidence was inconclusive about the eHects of scaling and root planning plus antibiotics compared to supragingival scaling. There is no
reliable evidence available regarding secondary prevention of CVD in people diagnosed with chronic periodontitis and CVD. Further trials
are needed to reach conclusions about whether treatment for periodontal disease can help prevent occurrence or recurrence of CVD.
P L A I N   L A N G U A G E   S U M M A R Y
Treating chronic gum inflammation (periodontitis) to prevent heart and blood vessel (cardiovascular) disease
Review question
The main question addressed by this review was whether treatments for chronic periodontitis (gum inflammation) can prevent or manage
cardiovascular (heart and blood vessel) diseases.
Background
Chronic periodontitis causes swollen and painful gums, and loss of the alveolar bone that supports the teeth. 'Chronic' is a label that
means the disease has continued for some time without treatment. The term 'chronic periodontitis' is being phased out as there is a new
system for categorising diHerent types of gum disease, but we have used this term in our review because the studies we found were based
on the old system.
There may be a link between periodontitis and cardiovascular diseases. The treatment for chronic periodontitis gets rid of bacteria and
infection, and controls inflammation, and it is thought that this may help prevent the occurrence or recurrence of diseases of the heart
and blood vessels. We wanted to find out whether periodontal therapy could help prevent death, or reduce the likelihood of having
cardiovascular 'attacks' like a stroke or heart attack.
Study characteristics
We searched for scientific research studies known as 'randomised controlled trials', up to 17 September 2019. In this type of study,
participants are assigned in a random way to an experimental or control group. People in the experimental group receive the treatment
being tested, and people in the control group usually receive either no treatment, placebo (fake treatment), another type of treatment or
routine care.
We found two studies to include in our review. One study assessed 165 participants who did not have cardiovascular diseases, but had
metabolic syndrome (a combination of risk factors for cardiovascular disease, such as obesity, high blood pressure, and high blood sugar).
The other study started oH with 303 participants who had cardiovascular diseases, but aNer a year, only 37 participants were assessed and
so we thought the results were not be reliable enough to be used. Both studies had problems with their design, and we judged them to
be at high risk of bias.
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Key results
For people who have metabolic syndrome but no cardiovascular diseases, we were unable to determine whether treating chronic
periodontitis, by removing the plaque and tartar ('scaling') from the roots of teeth and giving antibiotics, reduced the risk of dying or having
cardiovascular attacks when compared with scaling the teeth from above the gumline only.
For people with cardiovascular diseases and chronic periodontitis, we found no reliable evidence about the eHects of periodontal
treatment.
Certainty of the evidence
We classified the evidence as 'very low certainty'. We are uncertain about the findings because there are only two small studies, at high risk
of bias, with very imprecise results. Overall, we cannot draw any reliable conclusions from the findings. Further research is needed.
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis (Review)








































































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Primary prevention: scaling and root planing (SRP) plus antibiotics versus supragingival scaling for
people with periodontitis and metabolic syndrome
Primary prevention: scaling and root planing (SRP) plus antibiotics versus supragingival scaling
Population: people with periodontitis and metabolic syndrome
Settings: hospitals
Intervention: scaling and root planing (SRP) plus antibiotics
Comparison: supragingival scaling
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes








































*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio
GRADE Working Group grades of evidence
High certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low certainty: we are very uncertain about the estimate.


































































































































































bDowngraded two levels due to serious imprecision
 
 
Summary of findings 2.   Secondary prevention: periodontal treatment (scaling and root planing plus advice) versus community care (advice only) for
the management of cardiovascular disease in people with chronic periodontitis
Secondary prevention: periodontal treatment versus community care
Population: people with cardiovascular disease and chronic periodontitis
Settings: hospitals
Intervention: periodontal treatment – scaling and root planing (SRP) plus advice
Comparison: community care – advice only
Illustrative comparative risks*
Assumed risk Corresponding risk
Outcomes
Community care (advice only) Periodontal treat-











All-cause death Outcome not reported
All CVD-related death Outcome not reported
All cardiovascular
events
Follow-up: 6 to 25
months
One study of 303 participants assessed this outcome; however, we considered data were un-
reliable as participants were followed up for different lengths of time, and.only just over 10%




*The basis for the assumed risk is the control group risk in the one included study. The corresponding risk (and its 95% confidence interval) is based on the assumed risk
in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; CVD: cardiovascular disease; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low certainty: we are very uncertain about the estimate.
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B A C K G R O U N D
Description of the condition
Cardiovascular disease (CVD) covers a wide array of disorders
(including diseases of the cardiac muscle and the vascular system
supplying the heart, brain and other vital organs), such as coronary
heart disease (with narrowing or blockage of the coronary arteries,
which can cause angina and myocardial infarction) and stroke
(with narrowing, blockage or haemorrhage of the cerebrovascular
system), which are the world's largest killers, causing the death of
17.1 million individuals per year (Nabel 2003; Jamison 2006). There
are a variety of risk factors involved in the pathogenesis of CVD, such
as smoking or passive smoking (Law 1997; He 1999; Kallio 2010),
hypertension (Di'Auto 2019), excess sodium intake (Strazzullo
2009), and hyperlipidaemia (Austin 1999). Numerous successful
modalities of treatment that are based on these aetiological or
risk factors have been developed (Law 2009; Manktelow 2009; Rees
2013). However, in modern society, people are increasingly exposed
to such factors, and the aforementioned therapies are still not
enough, thus, the incidence of CVD increases year on year (WHO
2007).
Recently, considerable attention has been paid to the aetiological
role of acute or chronic infections on CVD; infections that
accelerate vascular inflammation and promote thrombosis of
vascular vessels (Herzberg 2005; Viles-Gonzalez 2006), are believed
to be a secondary pathogenic pathway (Smeeth 2004; Hansson
2006; Moutsopoulos 2006). Among the infections, periodontitis
might be the most common. It is an infectious disease resulting in
inflammation within the supporting tissues of teeth, resulting in
progressive attachment and alveolar bone loss (Armitage 1999). In
the last century, periodontitis was reported to aHect 6% to 20% of
the population (Oliver 1991; AAP 1999); and the estimate of disease
in the USA exceeds 47%. In those over 65 years, 64% have either
moderate or severe periodontitis (Eke 2012).
The label 'chronic periodontitis' has not been retained in the new
classification for periodontal diseases, which was developed at a
World Workshop run by the American Academy of Periodontology
(AAP) and the European Federation of Periodontology (EFP) in
2017 (Caton 2018). For this version of the review, we are retaining
the descriptor 'chronic', and the new classification will be used in
the next review update. The British Society of Periodontology has
published a flowchart to assist dental practitioners to implement
the new classification (see British Society of Periodontology
flowchart).
There are two reasons why periodontitis and CVD are believed
to be related. First, the levels of systemic inflammation increase
when moderate or severe periodontitis is present, and when
treating periodontitis, there is a clear reduction in the clinical signs,
with a decrease in the levels of systemic inflammatory mediators
(Tonetti 2007; Paraskevas 2008). Secondly, the periodontal
bacteria may invade the damaged periodontal tissue, enter
the bloodstream, and further invade the cardiovascular system.
Several periodontal pathogens, such as Porphyromonas gingivalis,
Bacteroides forsythus, Prevotella intermedia and Aggregatibacter
actinomycetemcomitans have been detected in carotid atheromas
by polymerase chain reaction (Haraszthy 2000; Padilla 2006).
Experimental studies have shown that the presence of these
periodontal pathogens and oral bacteria in the atheromas could
induce platelet activation and aggregation through collagen-like
platelet aggregation-associated protein expression. The activated
and aggregated platelets could then play an important role in
atheromatous formation and thrombosis, and finally lead to
cardiovascular events (Herzberg 1983; Herzberg 1996). Besides
this, periodontal bacteria may play a role in the formation
of coronary atherosclerotic plaques, which is indirectly proven
by the presence of bacterial DNA from the oral pathogenic
micro-organisms in coronary atherosclerotic plaques and the
special characteristics of the aortic aneurysms in cardiovascular
disease patients harbouringP. gingivalis (Mahendra 2010; Nakano
2011). They can induce cell-specific innate immune inflammatory
pathways, causing and maintaining a chronic state of inflammation
at sites distant from the periodontitis (Hayashi 2010). An
indirect association between the two diseases was identified by
investigators, as they share similar risk factors, such as smoking,
diabetes mellitus, obesity, and hypertension (Friedewald 2009; Han
2017). The association between periodontitis and CVD was proven
by clinical trials, and further confirmed by meta-analysis (Janket
2003; Scannapieco 2003; Khader 2004). Based on this evidence,
some investigators have concluded that there could be a mild to
moderate association between periodontitis and CVD (Genco 2002;
Hujoel 2002; Hansen 2016).
As a relationship between periodontitis and CVD is evident, it is
rational to explore whether CVD can be managed, or its occurrence
or recurrence prevented, by treating periodontitis.
Description of the intervention
It is believed that bacterial infection is the main aetiological factor
for periodontitis. Other factors, such as occlusal trauma, calculus,
and smoking are considered risks for accelerating the progression
of periodontitis (Meng 2009). Fortunately, there are several eHective
ways to control these factors, and further control periodontitis.
Supragingival and subgingival scaling and root planing (SRP)
could remove the periodontal bacteria or calculus, and create
a relatively healthy environment to reduce bacterial regrowth
(Eberhard 2015; Lamont 2018). Occlusal adjustment has also been
suggested as a means to eliminate the harmful occlusal trauma
that induces abnormal stress on the periodontal tissue (Foz 2012).
Periodontal surgery, including guided tissue regeneration, replaces
the lost or necrotic bone and periodontal tissue (Esposito 2009).
All of these therapies play a role in reducing the biofilm, or
number of bacteria, and controlling the accelerating factors. Such
maintenance and preventive interventions should be adopted
for periodontitis suHerers as a life-long commitment to control
periodontal inflammation and disease recurrence.
Periodontal medicine is now a recognised discipline, which aims
to treat the systemic diseases that are suspected to be associated
with periodontal disease, by applying periodontal therapies. One
Cochrane Review found low-quality evidence that periodontal
treatment (scaling and root planing) may help control diabetes
mellitus in the short term (Simpson 2015); another found low-
quality evidence that periodontal therapy may reduce low birth
weight (less than 2500 g (Iheozor-Ejiofor 2017)).
How the intervention might work
Periodontal therapy may clean up the infectious sources and
control the acceleration of periodontitis. Some studies have
already confirmed that high blood pressure can be lowered
and serum inflammatory markers, such as interleukin-6 (IL-6)
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis (Review)
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and C-reactive protein (CRP) can be significantly reduced aNer
such treatment (D'Aiuto 2005; Blum 2007; Martin-Cabezas 2016).
Tüter and colleagues indicated that periodontal therapy with a
subantimicrobial dose of doxycycline could increase serum levels
of apolipoprotein-A and high-density lipoprotein, reduce total
cholesterol levels, and further decrease the risk of cardiovascular
events (D'Aiuto 2005; Tüter 2007). However, as mentioned
previously, periodontitis and CVD may have similar risk factors
(smoking, obesity, hypertension, and diabetes mellitus), some of
which are modifiable and some of which are non-modifiable. The
mechanism of action of periodontal therapy for the management
of CVD is still unknown; it may control periodontitis directly,
change modifiable risk factors, or both. In addition, there is
insuHicient evidence to determine the superiority of diHerent
protocols or adjunctive strategies to improve tooth maintenance
during supportive periodontal therapy for the general population
(Manresa 2018). It remains unclear whether adjuvant therapy could
facilitate the eHects of periodontal therapy in the management of
CVD.
Why it is important to do this review
Cochrane Oral Health undertook an extensive prioritisation
exercise in 2014 to identify a core portfolio of titles that were the
most clinically important ones to maintain on the Cochrane Library
(Worthington 2015). This review was identified as a priority title by
the periodontal expert panel (Cochrane Oral Health priority review
portfolio). This is the second update of a review originally published
in 2014 and first updated in 2017 (Li 2014; Li 2017).
O B J E C T I V E S
To investigate the eHects of periodontal therapy for primary or
secondary prevention of cardiovascular disease in people with
chronic periodontitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCT) that aimed to test
the eHects of diHerent periodontal therapies for people diagnosed
with chronic periodontitis, with or without cardiovascular disease
(CVD), with follow-up times of at least one year. The studies could
be primary prevention studies or secondary prevention studies.
In the former, the focus would be on using periodontal treatment
to prevent the occurrence of CVD. Participants in the secondary
prevention studies would have CVD, or have been previously
diagnosed with CVD, so the focus would be on preventing
recurrence.
Types of participants
We considered trials with participants who met the following
criteria, regardless of age, sex, race, social or economic status.
1. Diagnosis of at least moderate chronic periodontitis with
pocketing greater than or equal to 4 mm.
2. Absence of any known genetic or congenital heart defects and
aggressive periodontitis.
3. For primary prevention, no existing or previous diagnosis of CVD
(including angina, myocardial infarction, stroke); for secondary
prevention, an existing or previous diagnosis of CVD.
4. Absence of other sources of inflammation, such as pulpal
infections and active caries.
5. No periodontal treatment within preceding six months
(participants should have active disease and not be in a
periodontal maintenance programme).
We did not include participants for whom periodontal therapy was
contraindicated (including pregnant or lactating women, people
with severe systemic diseases other than CVD), or participants who
were unable to complete assessments during the follow-up period.
Types of interventions
• Experimental: periodontal therapy of subgingival scaling and
root planing (SRP), or SRP in combination with systemic
antibiotic or host modulation, with or without other active
remedies.
• Control: maintenance therapy (supragingival scaling,
antimicrobial rinses), or no periodontal treatment, with or
without the same basic remedies as those in the intervention
group.
Types of outcome measures
We classified outcomes as primary (the main outcomes we
considered when drawing conclusions) and secondary. We
considered only long-term outcomes, i.e. those measured at one
year or more.
Primary outcomes
1. All-cause and CVD-related death
2. All cardiovascular events (angina, myocardial infarction, stroke)
Secondary outcomes
1. Modifiable cardiovascular risk factors: blood pressure; lipids
including cholesterol, triglycerides, low-density lipoprotein
cholesterol, very low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol
2. Blood test results, including serum levels of high-sensitivity C-
reactive protein (hs-CRP), apolipoprotein-A, apolipoprotein-B
3. Heart function parameters (such as ejection fraction)
4. Revascularisation procedures
5. Adverse events due to periodontal therapy (e.g. tooth sensitivity,
mouth discomfort)
Search methods for identification of studies
Electronic searches
Cochrane Oral Health’s Information Specialist conducted
systematic searches in the following databases for RCTs and
controlled clinical trials, with no language, publication year, or
publication status restrictions:
• Cochrane Oral Health’s Trials Register (searched 17 September
2019; Appendix 1);
• Cochrane Central Register of Controlled Trials (CENTRAL; 2019,
Issue 8) in the Cochrane Library (searched 17 September 2019;
Appendix 2);
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis (Review)
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• MEDLINE Ovid (1946 to 17 September 2019; Appendix 3);
• Embase Ovid (1980 to 17 September 2019; Appendix 4).
• CINAHL EBSCO (Cumulative Index to Nursing and Allied Health
Literature; 1937 to 17 September 2019; Appendix 5);
• OpenGrey (searched 17 September 2019; Appendix 6).
We modelled subject strategies on the search strategy designed
for MEDLINE Ovid. Where appropriate, we combined them with
subject strategy adaptations of the highly sensitive search strategy,
designed by Cochrane for identifying RCTs and controlled clinical
trials, as described in the Cochrane Handbook for Systematic
Reviews of Interventions Chapter 6 (Lefebvre 2011).
We also searched the following databases:
• Chinese BioMedical Literature Database (CBM; 1978 to 29 August
2019);
• China National Knowledge Infrastructure (CNKI; 1994 to 29
August 2019);
• VIP (1989 to 29 August 2019).
The search attempted to identify all relevant studies, irrespective of
language. We translated non-English papers.
Searching other resources
Cochrane Oral Health's Information Specialist searched the
following databases for ongoing trials:
• US National Institutes of Health Trials Register (http://
clinicaltrials.gov; to 17 September 2019; Appendix 7);
• World Health Organization (WHO) Clinical Trials Registry
Platform (http://apps.who.int/trialsearch/default.aspx; to 17
September 2019; Appendix 8).
We also searched Sciencepaper Online (2003 to 29 August 2019).
We checked the reference lists of all eligible trials for additional
studies. We contacted the first authors of all included studies
by email for any ongoing or unpublished studies examining the
eHicacy and safety of periodontal therapy for the prevention of CVD.
Handsearching
We handsearched all the Chinese professional journals and some
important English journals in the dental and cardiovascular fields
from the first issue to May 2011. We handsearched some of the
important English journals to May 2019 (see Table 1 and Table 2 for
details).
We checked that none of the included studies in this review were
retracted due to error or fraud.
We did not perform a separate search for adverse eHects of
interventions used; we considered adverse eHects described in
included studies only.
Data collection and analysis
Selection of studies
Two review authors (Wei Liu and Yubin Cao) carried out the study
selection in duplicate, according to the selection criteria. We had
designed the search to be sensitive, and include controlled clinical
trials, which we filtered out early in the selection process if they
were not randomised. We initially screened the titles and abstracts
from the search results to look for possible eligible studies. We
retrieved full texts of these studies, which were independently
assessed by both review authors to further assess eligibility.
We discussed any disagreements on study inclusion to reach
consensus, and when necessary, a third review author arbitrated.
We developed a PRISMA flow diagram of the whole process, as
recommended (Liberati 2009).
Data extraction and management
Two review authors (Wei Liu and Yubin Cao) carried out
the data extraction in duplicate. Disagreements were resolved
by discussion, and an arbitrator was involved when the
disagreement remained unresolved. We designed a customised
data extraction form, using MicrosoN Access 2007, in accordance
with guidance from the Cochrane Handbook for Systematic Reviews
of Interventions version (Higgins 2011). We pilot-tested this, using a
sample of the studies focusing on this topic, and then applied it to
all the included studies. We collected the following data.
• Source: study identification (ID), reviewer ID, citation, and
contact details.
• Eligibility: reasons for inclusion and exclusion.
• Methods of the study: centres and their location, duration,
design, sequence generation, allocation concealment, blinding,
and statistical methods.
• Participants: total number, setting, age and sex, diagnostic
criteria for both cardiovascular disease and periodontitis,
inclusion and exclusion criteria.
• Interventions: number of groups; content details, including
periodontal therapy, control treatment, and other active
treatment; time, frequency, dose, and usage of drugs
administered.
• Outcomes: definition of measures and units of the
measurements, time points of measurement, sample size
calculation, number of participants allocated to each group,
numbers lost to follow-up and the reasons, detailed summary
data for each group.
• Miscellaneous: funding, key conclusions, whether we required
correspondence, and miscellaneous comments from review
authors.
For studies that had multiple groups, we had planned to extract
data for all groups relevant to this review and record these in the
'Characteristics of included studies' section.
Where there was any missing information, we contacted the
original investigators of the included studies for clarification.
Assessment of risk of bias in included studies
We carried out 'Risk of bias' assessments, following the approach
described in Chapter 8 of the Cochrane Handbook for Systematic
Reviews of Interventions version (Higgins 2011). We contacted
authors of the included studies by email to obtain or clarify any
unreported or unclear information on the risk of bias of the
studies. Two review authors (Wei Liu and Yubin Cao) independently
assessed the risk of bias according to the published article and the
trial authors' responses. They discussed any discrepancies, and a
third review author arbitrated when necessary.
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis (Review)
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Risk of bias assessment of the included studies
We judged the risk of bias in each of the included studies for seven
domains (as identified in the Cochrane 'Risk of bias' tool). For each
of the following domains, we assigned a judgment of low, high, or
unclear risk of bias.
1. Random sequence generation: selection bias (biased allocation
to interventions) due to inadequate generation of a randomised
sequence.
2. Allocation concealment: selection bias (biased allocation to
interventions) due to inadequate concealment of the allocation.
3. Blinding of participants and personnel: performance bias due
to knowledge of the allocated interventions by participants and
personnel during the study.
4. Blinding of outcome assessment: detection bias due to
knowledge of the allocated interventions by outcome assessors.
5. Incomplete outcome data: attrition bias due to amount, nature,
or handling of incomplete outcome data.
6. Selective reporting: reporting bias due to selective outcome
reporting.
7. Other bias: bias due to problems not covered elsewhere in the
table, such as baseline imbalance, confounding, contamination
and co-interventions, etc.
We assessed the overall risk of bias for each study as:
• low risk of bias, where there was a low risk of bias for all domains,
or any plausible bias was unlikely to seriously alter the study
results;
• unclear risk of bias, where there was an unclear risk of bias for
one or more domains, or any plausible bias raised some doubt
about the study results; or
• high risk of bias, where there was a high risk of bias for one
or more domains, or any plausible bias might seriously weaken
confidence in the results.
Measures of treatment e=ect
Our selection of statistical methods was dependent on whether
the data were dichotomous, continuous, or presented as time-to-
event. We treated both primary outcomes as dichotomous data or
time-to-event data.
For dichotomous data, we calculated risk ratios (RR) and 95%
confidence intervals (CIs). We used the Peto odds ratio (Peto OR)
with 95% CI if the incidence of the events observed was very low.
For continuous data, we calculated mean diHerences (MD) and
95% CIs for change from baseline or the final values, if they
were measured by similar indices. If the data had been measured
using diHerent indices, we would have used standardised mean
diHerences (SMD) and 95% CIs.
Unit of analysis issues
We had planned to analyse cluster-randomised trials and studies
with more than two intervention groups diHerently from RCTs. For
cluster-randomised trials, to avoid any inappropriate analyses in
the original studies, we would have adopted approximate analyses-
eHective sample sizes, following the guidance of the first edition
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). For studies with more than two intervention
groups, as each meta-analysis addressed only a single pair-wise
comparison, we would have considered two approaches. The first
was to combine groups to create a single pair-wise comparison;
if this first approach failed, we had planned to select the most
relevant pair of interventions.
Dealing with missing data
For trials with missing data, we contacted the trial authors for
clarification and supplementation of the data. If there was no
reply, we planned to adopt the following statistical methods,
following guidance in the first edition of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). If the standard
deviation (SD) of the continuous data was not reported, we would
calculate it: (i) from the standard error (SE), 95% CIs, P values or
t values, ranges or interquartile ranges reported in the article; or
(ii) if the SD of change from baseline values was missing, we would
calculate it using the correlation coeHicient. We planned to conduct
Intention-to-treat (ITT) analysis if there were suHicient data. If ITT
could not be adopted, we planned to analyse the available data and
interpret results with caution
Assessment of heterogeneity
We planned to use the Chi2 test for heterogeneity to examine if
heterogeneity existed among the included studies. We used the I2
statistic to estimate the impact of the heterogeneity:
• 0% to 40% may indicate slight heterogeneity;
• 30% to 60% may indicate moderate heterogeneity;
• 50% to 90% may indicate substantial heterogeneity;
• 75% to 100% may indicate very substantial (considerable)
heterogeneity.
Assessment of reporting biases
To avoid reporting biases, we carried out a comprehensive search
that included grey literature and ongoing studies (see Search
methods for identification of studies). We planned to assess
publication bias and other reporting biases with the help of funnel
plots, if there were more than 10 trials providing results for one
outcome. Asymmetry of the funnel plot could suggest potential
publication bias, and would have been further tested by the
methods introduced by Egger 1997 (continuous outcomes) and
Rücker 2008 (dichotomous outcomes).
Data synthesis
We had planned to pool data if there was more than one study with
similar comparisons that reported the same outcome, using a fixed-
eHect meta-analysis model for two or three studies, and random-
eHects for four or more.
The method of meta-analysis for computing diHerent kinds of data
varied. We used the Review Manager 5 default fixed-eHect model,
Mantel-Haenszel method, for dichotomous data and calculated
MD or SMD for continuous data, unless the data were only in the
appropriate form for generic inverse variance for continuous data
(Review Manager 2014). In addition, we planned to use the Peto or
inverse variance method for time-to-event data.
Subgroup analysis and investigation of heterogeneity
Had there been suHicient studies, we would have investigated
any heterogeneity by carrying out subgroup analyses according to
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the diHerent courses and instruments of periodontal therapy and
diHerent adjuvant treatments.
Sensitivity analysis
To test the stability of the conclusions, we had planned to carry
out sensitivity analyses based on diHerent assumptions, such as
excluding studies with evident biases, using diHerent methods
to deal with missing data, diHerent models of meta-analysis,
exclusion of studies causing significant statistical heterogeneity,
or ITT analysis. We would have reported the results in detail, and
evaluated their impact on the stability of the conclusions, in the
discussion section.
Summary of main results
To provide key information on the eHects and safety of periodontal
therapy for CVD management in a quick and accessible format,
we developed a 'Summary of findings' table for each comparison.
This shows the certainty of the body of evidence for the primary
outcomes (all-cause death, all CVD-related death, all cardiovascular
events). Our assessment of the body of evidence involved
consideration of risk of bias at the outcome level, directness of the
evidence, heterogeneity, precision of eHect estimates, and risk of
publication bias (see Assessment of reporting biases). We used the
GRADE system to evaluate the certainty of the evidence for each
comparison and outcome, and GRADEpro GDT soNware (Atkins
2004; Guyatt 2008; Higgins 2011; GRADEpro GDT). We assessed the
certainty of the evidence as high, moderate, low, or very low.
R E S U L T S
Description of studies
Results of the search
We identified a total of 1801 records from electronic searches
and handsearching. ANer removing duplicates, we screened 1139
records by scanning the titles and abstracts. We considered 56
records to be potentially eligible, and obtained the full texts for
further consideration. We excluded 39 published studies, reported
in 44 articles. There are five ongoing studies (see Characteristics
of ongoing studies). One study is awaiting classification, because
the authors have not responded to requests for more information
about the eligibility criteria (Zhao 2016; see Characteristics of
studies awaiting classification). We included two studies (reported
in six articles) in this review (PAVE 2008; Lopez 2012). A flow diagram
illustrating the study selection process is shown in Figure 1.
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Figure 1.   Study flow diagram
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Figure 1.   (Continued)
 
Included studies
We included two RCTs in this review (PAVE 2008; Lopez 2012). See
the Characteristics of included studies tables for full details.
1. Primary prevention
We included one primary prevention study, which was a parallel-
arm, double-blind RCT of one-year duration, in 165 participants
with metabolic syndrome and periodontitis (Lopez 2012).
Participants
Participants were eligible if they were aged 35 to 65 years, had
periodontitis and metabolic syndrome, and retained ≥ 14 teeth. The
diagnostic criteria for periodontitis were the presence of four or
more teeth with one or more sites with probing depth (PD) ≥ 4 mm
and concomitant clinical attachment loss of ≥ 3 mm. The diagnosis
of metabolic syndrome was made when ≥ 3 of the following risk
determinants were present: 1) central obesity (> 102 cm in males;
> 88 cm in females) or body mass index (BMI) > 30 kg/m2; 2)
dyslipidaemia defined by plasmatic triglycerides level > 150 mg/dL;
3) high-density lipoprotein cholesterol (HDL) < 40 mg/dL in males
or < 50 mg/dL in females; 4) blood pressure ≥ 130/85 mmHg; or 5)
fasting glucose ≥ 110 mg/dL.
Intervention
Participants in the experimental treatment group received
supragingival and subgingival scaling, crown polishing, and root
planing under local anaesthesia using ultrasound and hand
instruments, and oral hygiene instruction. In addition, one
week before beginning root planning, participants were given
metronidazole (250 mg) and amoxicillin (500 mg) tablets, three
times daily, for seven days.
Control
Participants in the control treatment group received a treatment
consisting of supragingival scaling with ultrasound instruments,
crown polishing, and two placebo tablets three times daily, for
seven days. The metronidazole, amoxicillin, and placebo tablets
were identical in appearance.
Outcomes
Risk factors for cardiovascular disease were recorded; serum
lipoprotein cholesterol, glucose, body mass index (BMI), C-
reactive protein (CRP) and fibrinogen concentrations, and clinical
periodontal parameters were assessed at baseline and every
3 months until 12 months aNer therapy. Participants with
intercurrent systemic infections during the study period were
excluded from the analysis of parameters above aNer the
intercurrent infections were detected. All cardiovascular events,
including myocardial infarction and stroke, were recorded.
2. Secondary prevention
We included one secondary prevention study, which was a multi-
centre, parallel-group, single-blind RCT, with 303 participants
randomised into a periodontal therapy group or community care
group (PAVE 2008).
Participants
Participants had to have ≥ 50% blockage of one coronary artery
or have had a coronary event within the preceding three years
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(but at least three months before selection for study participation).
The periodontal inclusion criteria were: the presence of at least
six natural teeth, including third molars, with at least three teeth
with probing pocket depth (PPD) ≥ 4 mm, at least two teeth with
interproximal clinical attachment loss (CAL) ≥ 2 mm, and ≥ 10% of
sites having bleeding on probing (BOP).
Intervention
The intervention group (N = 151) received oral hygiene instruction
and one regimen of full-mouth scaling and root planing (SRP) with
local anaesthesia (30% of the treatment was completed more than
two months aNer randomisation). Only 92.7% of the participants
received the treatment; one participant received SRP outside the
study.
Control
Participants in the control group (community care group; N = 152)
received oral hygiene instruction and were given a copy of their
oral radiographs, with a letter stating the tentative oral findings;
investigators recommended they seek the opinion of a dentist (9%
of the participants in the control group got SRP outside the study
within six months and 11% of them got SRP within the entire follow-
up period).
Outcomes
The participants were observed for between 6 and 25 months. The
following outcomes were reported: serious cardiovascular adverse
events (all cardiovascular events), serum high-sensitivity C-reactive
protein (hs-CRP), number of participants who had high hs-CRP, and
adverse events measured as the development of an undesirable
medical or dental condition, or the deterioration of a pre-existing
medical or dental condition, following or during exposure to a
pharmaceutical product or medical or dental procedure, whether
or not investigators considered it was causally related to the
intervention. Data on adverse events due to periodontal therapy
were analysed in this review.
Excluded studies
We excluded 39 studies (44 articles) for the following reasons:
follow-up was less than one year (14 studies); study was not an
RCT (10 studies); there were no CVD patients or CVD outcomes
(4 studies); participants in the intervention group did not get any
active periodontal therapy (2 studies); participants were pregnant
(2 studies); study did not evaluate periodontal therapy (1 study); the
same therapy was provided to both groups (1 study); participants
did not have periodontitis (1 study); half of participants had
aggressive periodontitis (1 study); participants had rheumatoid
arthritis (1 study); participants were receiving maintenance therapy
(1 study) (see Characteristics of excluded studies tables).
Risk of bias in included studies
We assessed both studies as being at high risk of bias overall. See
the Characteristics of included studies tables and Figure 2.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study
 
Allocation
Lopez 2012 used computer-generated randomisation for the first
eight participants enrolled, and the minimisation method for the
following participants, then allocated participants using opaque
envelopes with cardboard inside so they were impermeable
to light. However, the authors did not perform randomisation
according to the protocol, but changed the method during the
trial. Hence, we assessed it at unclear risk of bias for sequence
generation and at low risk for allocation concealment.
PAVE 2008 used a computer-generated randomised table and used
central allocation. We assessed it at low risk bias for both random
sequence generation and allocation concealment.
Blinding
Due to the nature of the interventions, it was impossible to achieve
blinding of participants and personnel in either study. Therefore,
we assessed both studies at high risk of performance bias.
Blinding of outcome assessment was described in both studies, so
we considered them at low risk of detection bias.
Incomplete outcome data
Only 3% of participants were lost to follow-up and excluded from
the analysis in Lopez 2012, so we judged it at low risk of bias. Only
37 of the 303 participants received follow-up at one year, thus we
assessed PAVE 2008 at high risk of attrition bias.
Selective reporting
We assessed both studies at low risk of bias because variables were
reported as stated.
Other potential sources of bias
We did not identify any other potential sources of bias in Lopez
2012. For PAVE 2008, 92.7% of participants in the treatment group
received the treatment. One participant in the intervention group
received SRP outside the study. Eleven per cent of participants in
the control group had received SRP by the end of the follow-up
period. We assessed this as high risk of bias due to contamination
and co-interventions.
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E=ects of interventions
See: Summary of findings for the main comparison Primary
prevention: scaling and root planing (SRP) plus antibiotics versus
supragingival scaling for people with periodontitis and metabolic
syndrome; Summary of findings 2 Secondary prevention:
periodontal treatment (scaling and root planing plus advice)
versus community care (advice only) for the management of
cardiovascular disease in people with chronic periodontitis
1. Primary prevention
1.1 Scaling and root planing (SRP) plus antibiotics versus
supragingival scaling
One study evaluated this comparison. The experimental group
used amoxicillin and metronidazole while the control group used
two placebos (Lopez 2012). Both groups received oral hygiene
instruction and were provided with toothbrushes and toothpaste.
1.1.1 All-cause death
It is uncertain whether SRP and antibiotics can prevent death by
any cause at 12-month follow-up when compared to supragingival
scaling. One participant died due to fatal myocardial infarction in
the SRP plus amoxicillin and metronidazole group and there were
no deaths in the control group (Peto odds ratio (OR) 7.48, 95%
confidence interval (CI) 0.15 to 376.98; 165 participants; very low-
certainty evidence; Analysis 1.1).
1.1.2 All CVD-related death
As mentioned in the results of all-cause death, only one participant
died. It is uncertain whether SRP plus antibiotics can prevent CVD-
related death at 12-month follow-up compared to supragingival
scaling (Peto OR 7.48, 95% CI 0.15 to 376.98; 165 participants; very
low-certainty evidence; Analysis 1.2).
1.1.3 All cardiovascular events
SRP plus antibiotics might lead to an increase in cardiovascular
events at 12-month follow-up compared to supragingival scaling
(Peto OR 7.77, 95% CI 1.07 to 56.1; 165 participants; very low-
certainty evidence; Analysis 1.3). In the SRP plus antibiotics group,
four participants had cardiovascular events (one participant died
due to fatal myocardial infarction; one had an Ischaemic stroke
before the last root planing appointment; one had a stroke eight
weeks aNer periodontal therapy; and one had several small cerebral
hemorrhagic events seven months aNer periodontal therapy). No
participants had cardiovascular events in the supragingival scaling
plus two placebos group.
1.1.4 Blood test results
Based on the mixed-eHects linear regression analysis, it is uncertain
whether SRP plus antibiotics lead to a diHerence in C-reactive
protein (β coeHicient -0.002, 95% CI -0.19 to 0.20), or fibrinogen (β
coeHicient 10.9, 95% CI -12.0 to 33.8) levels between two treatment
groups (very-low certainty evidence).
1.1.5 Adverse events related to periodontal therapy
It is uncertain whether SRP plus antibiotics lead to a diHerence
in adverse events at 12-month follow-up when compared with
supragingival scaling (Peto OR 0.14, 95% CI 0.00 to 6.90; 165
participants; very-low certainty evidence; Analysis 1.4). One
participant in the supragingival scaling plus two placebos group
showed progression of periodontitis. One participant had a severe
allergic reaction to an environmental chemical, but it was not
attributed to periodontal therapy.
2. Secondary prevention
2.1 Periodontal treatment versus community care
Participants in the periodontal treatment group, who received
scaling and root planing (SRP) and oral hygiene instruction (OHI),
were compared with those in the community care group, who
received OHI, radiographs of their mouths, and a letter about the
findings, along with advice to contact a dentist (PAVE 2008).
2.1.1 All-cause death
Not reported.
2.1.2 All CVD-related death
Not reported.
2.1.3 All cardiovascular events
Because of variable follow-up periods (6 to 25 months) and the
loss to follow-up by one year being almost 90%, we did not
consider the results from this study to be useful for analysis. It is
therefore impossible to ascertain whether periodontal treatment
leads to a diHerence in cardiovascular events when compared with
community care.
2.1.4 Blood test results
Serum high-sensitivity C-reactive protein (hs-CRP) was tested at
one year. As the loss to follow-up was almost 90%, we did not
consider the data to be useful for analysis.
2.1.5 Adverse events related to periodontal therapy
Because of variable follow-up periods (6 to 25 months) and the loss
to follow-up by one year being almost 90%, we did not consider
the results from this study to be useful for analysis. It is therefore
uncertain whether adverse events are more likely with either of the
interventions.
D I S C U S S I O N
Summary of main results
The aim of the review was to evaluate the eHect of
periodontal treatment in the primary and secondary prevention of
cardiovascular disease for people with chronic periodontitis. We
included two randomised controlled trials (RCT) in the review.
• For primary prevention of cardiovascular disease (CVD) in
people with periodontitis and metabolic syndrome, it was not
possible to establish the eHects of scaling and root planing (SRP)
plus antibiotics compared to supragingival scaling on all-cause
mortality, all CVD-related death, all cardiovascular events, levels
of C-reactive protein (CRP) and fibrinogen, or adverse events due
to periodontal therapy (very low-certainty evidence).
• For secondary prevention, death was not an outcome in the
one relevant study; the variable follow-up periods and extremely
high loss to follow-up meant we could not draw any conclusions
about the eHect of periodontal treatment compared with
community care on all cardiovascular events, levels of CRP, or
adverse events due to periodontal therapy (very low-certainty
evidence).
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Because there were only two included studies, providing very low-
certainty evidence, we should treat the results cautiously.
Overall completeness and applicability of evidence
The review aimed to include both primary and secondary
prevention studies assessing periodontal therapy in people with
chronic periodontitis. The evidence from this review can be applied
to adults in most age groups, except those over the age of 75
years. The following outcomes are not covered in this review:
modifiable cardiovascular risk factors, heart function parameters,
and revascularisation procedures. For primary prevention, we must
emphasise that all participants were diagnosed with metabolic
syndrome, and it was unclear whether the results could be applied
to other populations. For secondary prevention, although the
investigators reported on adverse events and serious adverse
events, there is no indication that death (all-cause or CVD-related)
was an outcome of the trial. Therefore, this review does not provide
any understanding about the eHect of periodontal therapy on risk
of death for people with cardiovascular disease.
Clinicians should also understand that we only assessed the eHect
of periodontal therapy for the management of CVD. Timing of
periodontal therapy was not assessed. For people with CVD, it is
not safe to give active periodontal therapy to those have had a
stroke within six months, or who have systolic blood pressure >
180 mmHg/diastolic blood pressure > 110 mmHg, fasting blood
glucose > 7.0 mmol/L/HbA1c > 7.5%, platelet count < 60×109/L, or
international normalised ratio ≥ 1.5 to 2.0 (Renvert 2016; SP, CSA
2017). The results of this systematic review cannot be applied to
these individuals.
It is unclear to what level of periodontitis severity the results apply.
Lopez 2012 included participants who had least four sites with PD
≥ 4 mm. This could mean, for instance, that most participants had
only four sites that were 4 mm deep, in which case, the potential for
treatment to make a diHerence to local and systemic inflammation
was limited, which might reduce the potential to see diHerences in
CVD outcomes. Clinicians may be more interested in the eHects of
controlling severe periodontal inflammation on the systemic CVD
outcomes.
EHectiveness and intensity of the intervention were not clearly
described, which made it more diHicult to assess the applicability
of the evidence. The authors did not give detailed periodontal
therapy protocols for the participants. Lopez 2012 mentioned that
participants received periodontal treatment during the one-year
maintenance period, but the intensity was not specified.
The long-term control of periodontal inflammation also remained
unclear. Lopez 2012 reported a significant improvement (i.e.
lower score) of all the periodontal parameters compared to
baseline in the intervention and control groups three months
aNer therapy. However, they described equivocally that "their
values remained lower than at baseline, up to 12 months in both
groups", from which we could speculate that the periodontal
inflammation may not be well controlled at 12 months. PAVE
2008 did not report clinical periodontal parameters during one-
year follow-up. Long-term control of periodontal inflammation may
require surgical or further active non-surgical therapy to reach
clinical endpoints of periodontal therapy and periodontal health.
Without identified inflammatory control, the ability to discern the
contribution of oral inflammation to the risk of cardiovascular
and peripheral artery disease will remain unknown. One year
following non-surgical treatment, there could be participants with
disease recurrence or re-established periodontal plaque-induced
inflammation, confounding treatment outcomes in these RCTs.
If the periodontal therapy does not alleviate the periodontitis
eHectively, it may be impossible to prove that the eHects on CVD
outcomes are caused by the periodontal therapy. Further studies
addressing these flaws may improve methodological rigor and our
ability to reach credible conclusions.
Quality of the evidence
Both Lopez 2012 and PAVE 2008 were assessed at high risk of bias
(Figure 2). Data from PAVE 2008 were unusable due to particularly
high attrition bias. Therefore, all the evidence was downgraded due
to serious risk of bias.
Each analysis included only one study, thus none of the evidence
was downgraded for inconsistency.
The number of events was mostly insuHicient, reflected in the wide
confidence intervals, thus all the evidence was downgraded for
imprecision.
None of the evidence was downgraded for indirectness.
Due to the limited number of included studies, we did not generate
a funnel plot to examine publication bias across studies, thus none
of the evidence was downgraded for this.
Overall, all the evidence was graded as very low-certainty, due
to serious limitations of the two studies and the very imprecise
results (Summary of findings for the main comparison; Summary of
findings 2).
Potential biases in the review process
The protocol for this review underwent some minor changes
(DiHerences between protocol and review). Some of the changes
include a change in the definition of chronic periodontitis, to
include people with a pocket depth of 4 mm or more. The follow-
up period was also changed to at least one year, and heart function
parameters were included in the protocol as a secondary outcome.
These changes may be justified, but could still be a source of bias
in the review process.
Treatment for CVD might influence periodontal health.
Current research has indicated the antimicrobial eHect
of statins to Porphyromonas gingivalis and Aggregatibacter
actinomycetemcomitans (Emani 2014). Magán-Fernández 2014
concluded that intake of simvastatin is associated with increasing
serum osteoprotegerin concentrations, and this could have
a protective eHect against bone breakdown and periodontal
attachment loss. During the trial, investigators could not control the
use of CVD drugs, which could influence final periodontal health in
every group, and cause contamination.
Agreements and disagreements with other studies or
reviews
Other reviews focusing on the preventive or treatment eHects
of periodontal therapy and oral health promotion for the
management of cardiovascular disease have been published,
which show inconsistent results for the eHect of periodontal
therapy on systemic markers (Ioannidou 2006; Lam 2010; Roca-
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Millan 2018). The reviews are largely not comparable with this
present review because of the inadequate follow-up period.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
There is very limited evidence assessing the impact of periodontal
therapy on the prevention of cardiovascular disease, and it is
insuHicient to generate any implications for practice. Further trials
are needed before reliable conclusions can be drawn.
Implications for research
There is a need for more randomised controlled trials (RCT)
examining eHects of periodontal therapy on both the primary and
secondary prevention of CVD. We hope future studies will consider
the following issues.
• Participants: the target population of primary prevention could
extend to patients with high blood pressure, diabetes, and
hyperlipaemia etc.; in addition, it is important to stratify study
participants according to the severity of the periodontitis and
the number of remaining teeth. Again, confounding factors,
such as acute inflammation, smoking, and diabetes should be
carefully considered and controlled for.
• Intervention and comparison: periodontal therapy can be a
single- or multi-regimen of scaling and root planing (SRP). Since
the included studies only oHered a single regimen, new studies
could focus on the eHect of multi-regimen SRP in controlling
periodontitis. Intensity of interventions should be clearly
specified, including the plan for the maintenance therapy. The
CONSORT non-pharmacological intervention extension would
be helpful here to guide authors in being explicit (Boutron 2017).
In addition, multiple kinds of host modulation drugs could be
chosen.
• Outcomes: there is need for more studies reporting on all-cause
or cardiovascular-related deaths and cardiovascular events
observed aNer long-term follow-up of one year or more. Most
of the studies identified with our search strategy were excluded
on the basis of inadequate follow-up period. As we mentioned
in Agreements and disagreements with other studies or reviews,
we found that the results might be diHerent if short-term
results were incorporated into long-term data. In addition,
clinical periodontal data should be presented in order to
allow judgement about whether the periodontal therapy would
eHectively control participants' chronic periodontitis.
• Risk of bias: lack of compliance with study protocol and
incomplete follow-up of participants can be reduced, as
suggested by PAVE 2008, if participants are followed up
by a cardiologist. Although blinding of the participants and
personnel is diHicult to achieve in most periodontal RCTs,
blinded outcome assessment should be achievable. OHering
supragingival scaling to the control group might be useful for
blinding participants.
• Method of analysis: intention-to-treat analyses are encouraged
when loss to follow-up cannot be avoided.
PAVE 2008 is described as a 'pilot' study, and it would be helpful to
extend this, since a pilot would not be expected to show a definitive
desired outcome. We hope the research team will further explore
eHective methods to reduce the risk of bias, improve participant
compliance, and decrease the loss to follow-up.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods • Type of study: parallel-arm, double-blind RCT
• Stratification: randomisation was computer generated for the first 8 participants enrolled, whereas
the group assignment for the following participants was done using the minimisation method
• Sample size calculation: took into account the change in the CRP level as a result of therapy. Assuming
a mean difference between groups in CRP change of 0.60, with a standard deviation of 1, it was calcu-
lated that with 120 participants, 60 in each group, there would be 90% power to detect this difference
at a significance level (a) of 0.05. Because they expected a dropout rate of 35%, the sample size was
increased to 165
Participants • Centres: Dr. Eloisa Diaz Dental Center, San Jose Hospital, Santiago, Chile
• Inclusion criteria: participants were eligible if they were aged 35 to 65 years, had periodontitis and
MetS, and ≥14 teeth. Diagnostic criteria for periodontitis were the presence of 4 or more teeth with 1
or more sites with probing depth (PD) ≥ 4 mm and concomitant clinical attachment loss of ≥ 3 mm.
The diagnosis of MetS was made when ≥ 3 of the following risk determinants were present: (1) central
obesity (> 102 cm in males; > 88 cm in females) or body mass index (BMI) > 30 kg/m2; (2) dyslipidaemia
defined by plasmatic triglycerides level > 150 mg/dL; (3) high-density lipoprotein cholesterol (HDL) <
40 mg/dL in males or < 50 mg/dL in females; (4) blood pressure ≥ 130/85 mmHg; or (5) fasting glucose
≥ 110 mg/dL
• Exclusion criteria: history of PT; kidney, liver, or lung disease; any other chronic or acute infections
during the previous 6 months as assessed on clinical examination and routine laboratory testing; sys-
temic antibiotic treatment in the past 6 months, regular use of non-steroidal anti-inflammatory drugs,
hormone replacement therapy, pregnancy, and breastfeeding
• Participants type: periodontitis and MetS
• Number of participants: 165 (intervention group 82; control group 83)
• Sex of participants: male 46, female 119 (intervention group 24/58; control group 22/61)
• Age of participants: mean 55.24 (intervention group 54.13 ± 8.8; control group 56.33 ± 8.9)
• Lost to follow-up: 3 of 82 intervention participants and 2 of 83 control participants did not finish the
study
Interventions • Both groups had hopeless teeth extracted and caries lesions restored before periodontal treatment
started
Lopez 2012 
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• All participants received oral hygiene instruction; toothbrushes and toothpaste were provided to the
participants during the study
• Intervention group: supragingival and subgingival scaling, crown polishing, and root planing under
local anaesthesia. Metronidazole (250 mg) and amoxicillin (500 mg) tablets, 3 times daily, for 7 days,
1 week before beginning root planning
• Control group: supragingival scaling, crown polishing, and 2 placebo tablets 3 times daily, for 7 days
• At the maintenance visits, patients in the intervention group received supragingival and subgingival
plaque elimination and oral hygiene instructions, and patients in the control group received supragin-
gival plaque elimination and oral hygiene instructions. The participants were interviewed at all fol-
low-up visits to determine changes in diet, medication, smoking habits, physical activity, and signs of
intercurrent infections.
• Participants were advised not to suspend any medication for MetS management during the study pe-
riod
• Duration of follow-up: 12 months
Outcomes • Serum lipoprotein cholesterol, glucose, body mass index (BMI), CRP, fibrinogen concentrations and
periodontal parameters (PD, CAL, and BOP at 6 sites per tooth) were assessed at baseline and every
3 months until 12 months after therapy
• Total cholesterol, HDL, and low-density lipoprotein (LDL) cholesterol and glucose levels were quanti-
fied using standard laboratory procedures. Fibrinogen was assayed by the Clauss method, and high-
sensitivity CRP concentrations were determined using a high-sensitivity enzyme-linked immunosor-
bent assay with a lower detection limit of 10 ng/L
• Cardiovascular events (12 months follow-up)
Notes A significant improvement of all the periodontal parameters compared to baseline was observed in
the intervention group (P = 0.0001) and in the control group (P = 0.0001) at 3 months after therapy, and
their values remained lower than at baseline up to 12 months in both groups.
• Funding: National Fund for Scientific and Technological Development Research Grant
• Country: Chile
• Timeframe of the study: March 2007 to March 2009
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Randomization was computer generated for the first eight partici-
pants enrolled, whereas the group assignment for the following participants
was done using the minimization method to prevent an imbalance between
the groups related to sex, smoking status (current/former/never), hyperten-
sion (yes/no), and the extent of periodontitis, measured as the percentage of
sites with PD ≥ 4 mm (≤ 20% or > 20%)"
Comment: computer-generated randomisation and minimisation method
used. However, the authors did not perform randomisation according to the
protocol, but changed the randomisation method during the trial.
Allocation concealment
(selection bias)
Low risk Quote: "Concealment of treatment assignments was obtained by using
opaque envelopes with a cardboard inside to render them impermeable to
light, and the group allocation was revealed to the therapist on the day the PT
began. The examiner, the patients, and the technician who performed the lab-
oratory analyses were all blinded to group assignment"





High risk Quote: "The examiner, the patients, and the technician who performed the
laboratory analyses were all blinded to group assignment"
Lopez 2012  (Continued)
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Comment: blinding of participants adequately achieved, but it was not possi-
ble to achieve blinding of personnel
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "The examiner, the patients, and the technician who performed the
laboratory analyses were all blinded to group assignment"




Low risk Quote: "79 of 82 ETG patients and 81 of 83 CTG patients finished the study, at-
tending all the study visits"




Low risk Comment: all outcomes reported




Methods • Type of study: parallel RCT
• Stratification: randomisation was stratified by clinic and smoking status (whether participants were
smokers in the past 5 years)
• Sample size calculation: not reported
Participants • Centres: 5, the University at Buffalo, the University of North Carolina at Chapel Hill, Boston University,
Kaiser Permanente Center for Health Research/Oregon Health and Sciences University, and the Uni-
versity of Maryland, Baltimore, Maryland
• Inclusion criteria: cardiac and periodontal inclusion criteria. Cardiovascular criteria: participants had
to be ≤ 75 years of age with ≥ 50% blockage of one coronary artery or have had a coronary event with-
in 3 years but ≥ 3 months previously, including myocardial infarction, coronary artery bypass graN
surgery, or coronary transluminal angioplasty with or without a stent. Periodontal inclusion criteria:
presence of at least 6 natural teeth, including third molars, with at least 3 teeth with PPD ≥ 4 mm, at
least 2 teeth with interproximal CAL ≥ 2 mm, and ≥ 10% of sites having BOP. The criteria were applied
after accounting for tooth extractions that were deemed clinically necessary.
• Exclusion criteria: not reported
• Participants type: moderate to severe periodontitis and CVD
• Number of participants: 303 (intervention group 151; control group 152)
• Sex of participants: male 216, female 87 (intervention group 104/47; control group 112/40)
• Age of participants (mean ± SD): 59.6 years ± 8.8 years (intervention group 59.5 ± 9.1; control group
59.8 ± 8.7)
• Lost to follow-up: by the 6-month visit, 14 participants had withdrawn consent, and 7 had been lost
to follow-up. They were all considered drop-outs. Among follow-up participants, only 228 had clinical
follow-up. By 1 year, only 37 had clinical follow-up. Follow-up among the 37 participants was up to
25 months.
Interventions • Any hopeless teeth were extracted for participants before randomisation.
• Intervention group: oral hygiene instruction + full-mouth SRP under local anaesthesia (30% of the
treatment being completed > 2 months after randomisation; 92.7% of the participants received the
treatment; 85% of them received supragingival scaling)
• Control group (community care group): oral hygiene instruction and a copy of their oral radiographs
with a letter stating the tentative oral findings and recommendation to seek the opinion of a dentist
(9% of the participants in the control group got SRP outside the study within 6 months, and 11% of
them got SRP within the whole follow-up period)
PAVE 2008 
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• Besides the study treatment, some participants sought dental care in other ways (such as their own
dental providers); 1% of participants in the intervention group got SRP outside the study and 9% (6
months) and 11% (whole study follow-up) of the participants in the control group got SRP.
• Duration of follow-up: 6 to 25 months
Outcomes • Cardiovascular SAE (all cardiovascular events) measured during the whole study (trial authors stated
in an e-mail that this was 25 months)
• Serum hs-CRP (measured by latex-enhanced nephelometry) at baseline, 6 months, and 1 year
• Number of participants with high hs-CRP (serum hs-CRP > 3 mg/L) measured at baseline, 6 months,
and 1 year
• AE (development of an undesirable medical or dental condition, or deterioration of a pre-existing
medical or dental condition, following or during exposure to a pharmaceutical product or medical or
dental procedure, whether or not it was considered causally related to the intervention) measured
during the whole study
• SAE (an experience that is known with certainty, or suspected with good reason, to constitute a threat
to life, or to cause severe or permanent damage) measured during the whole study
Notes • The trial author provided extra information about the study.
• Funding: NIDCR grant
• Country: USA
• Timeframe of the study: January 2003 to June 2005
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomization was stratified by clinic and smoking status (whether
subjects were smokers in the past 5 years). A permuted block randomization
scheme was used with a random mixture of block sizes within each stratum."
In authors' letter "the randomisation was by computer using a random num-
ber generator in SAS"
Comment: random number generation was adequate
Allocation concealment
(selection bias)
Low risk Quote: "Clinical centre staH obtained treatment assignments through a Web-
based system designed and maintained by the coordinating centre. When a
participant was deemed eligible, a staH member used the Web interface to en-
ter the eligibility information, and the system returned the treatment assign-
ment"





High risk Comment: it was not possible to achieve participant and personnel blinding in
this study.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: authors' letter stated that "the outcome assessment was blinded".




High risk Comment: in one year, only 37/303 (12.2%) got clinical follow-up.
Selective reporting (re-
porting bias)
Low risk Comment: all the outcomes were reported.
PAVE 2008  (Continued)
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Other bias High risk Comment: about 92.7% of the participants in the treatment group received
the treatment. One participant in the intervention group received SRP outside
the study. 11% of the participants in the control group had received SRP by the
end of the follow-up period. Therefore, this study had contamination and co-
interventions.
PAVE 2008  (Continued)
AE = adverse events; BOP = bleeding on probing; CAL = clinical attachment level; CVD = cardiovascular disease; hs-CRP = high-sensitivity
C-reactive protein; MetS= metabolic syndrome; PPD = probing pocket depth; PT = periodontal therapy; RCT = randomised controlled trial;
SAE = serious adverse event; SD = standard deviation; SRP = scaling and root planing
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
ACTRN12605000593639 Participants in the intervention group did not get any active periodontal treatment
Bokhari 2012 Follow-up shorter than 1 year
Brown 2004 No participants had periodontitis
Cullinan 2015 Participants in the intervention group did not get any active periodontal treatment
D'Aiuto 2005 Follow-up shorter than 1 year
Dietrich 2005 A review article, not an RCT
Domínguez 2010 No cardiovascular patients involved, no CVD closely-related outcomes reported
Ebersole 1997 Not comparing periodontal treatment
El-Sharkawy 2010 No cardiovascular patients involved, no CVD closely-related outcomes reported
Elter 2006 Not an RCT
Emingil 2011 No cardiovascular patients involved, no CVD closely-related outcomes reported
Fajardo 2010 Participants got the same periodontal treatment in both groups
Golub 2002 No cardiovascular patients involved, no CVD closely-related outcomes reported
Gottehrer 2006 Not an RCT
Gottehrer 2007 Not an RCT
Gottehrer 2007a Not an RCT
Gunupati 2011 Not an RCT
Ide 2003 Follow-up shorter than 1 year
Ide 2004 Not an RCT
Kamil 2011 Follow-up shorter than 1 year
Lösche 2007 A review article, not an RCT
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Study Reason for exclusion
Michalowicz 2009 All the participants were pregnant
NCT00093236 Follow-up shorter than 1 year
NCT00681564 Follow-up shorter than 1 year
Offenbacher 2006 All the participants were pregnant
Ortiz 2009 All the participants had rheumatoid arthritis
Oz 2007 Follow-up shorter than 1 year
Paju 2006 Participants in the intervention group did not get any active periodontal treatment
Payne 2011 Participants were undergoing periodontal maintenance therapy
Sun 2010 Follow-up shorter than 1 year
Taylor 2010 Follow-up shorter than 1 year
Tonetti 2007 Follow-up shorter than 1 year
Tüter 2007 Follow-up shorter than 1 year
Tüter 2010 Follow-up shorter than 1 year
Ushida 2008 Follow-up shorter than 1 year
Vidal 2009 Follow-up shorter than 1 year
Wozakowska-Kapłon 2009 A review article, not an RCT
Yuan 2010 Not an RCT, it is a CCT
Zhao 2010 Half of the included participants had aggressive periodontitis
CCT = controlled clinical trial; CVD = cardiovascular disease; RCT = randomised controlled trial
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods • Type of study: three-armed parallel RCT
• Stratification: not reported
• Sample size calculation: not reported
Participants • Centres: 1, Taiyuan Central Hospital of Shanxi Medical University
• Inclusion criteria: (1) patients with moderate to severe periodontitis aged ≥ 40 years. The diagnosis
of periodontitis was made according to Armitage's classification system: gingivitis with bleeding
on probing, clinical attachment loss ≥ 3 mm for all the residual teeth, the alveolar bone resorption
≥ 1/3 of root length, the number of lost teeth < 14; (2) patients with ≥ 50% blockage of at least
one coronary artery, a medical history of myocardial infarction or angina ≥ 6 months, no acute
coronary event within 6 months, male ≥ 40 years old or female ≥ 45 years old, positive results of
exercise stress test, and at least two syndromes among diabetes, high blood pressure, and hyper-
cholestaeremia.
Zhao 2016 
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• Exclusion criteria: (1) systemic diseases except CVD (including infection, tumour, or progressive
liver disease); (2) periodontal treatment within 6 months; (3) evident malocclusion or invasive
periodontitis; (4) age < 40 years old
• Participants: moderate to severe periodontitis and CVD
• Number of participants: total 101; Group 1 – 34; Group 2 – 34; Group 3 – 33
• Sex of participants: not reported
• Age of participants: not reported
• Duration of follow-up: 24 months
Interventions • Group 1: periodontal treatment once per half year + oral hygiene instruction
• Group 2: periodontal treatment once per year + oral hygiene instruction
• Group 3: no periodontal treatment
• The periodontal treatment included supragingival scaling, subgingival scaling, and SRP. The pe-
riodontal treatment should be finished within two weeks and SRP in one month. 3% hydrogen
peroxide and iodine glycerin were locally administered
Outcomes All cardiovascular events (incidence proportion of myocardial infarction)
Notes This study was published in a local Chinese journal without a peer review process. We could not tell
whether the allocation method was 'random' or 'casual' from the text in Chinese. We attempted to
contact the corresponding author but failed.
• Funding: not reported
• Country: China
• Timeframe of the study: August 2012 to December 2012
Zhao 2016  (Continued)
hs-CRP = high-sensitivity C-reactive protein; LDL = low-density lipoprotein; RCT = randomised controlled trial; VLDL = very-low-density
lipoprotein
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Scientific title. Influence of periodontal treatment on systemic inflammatory mediators: hsC-reac-
tive protein, fibrinogen and white blood cells in CHD patients
Public title. Influence of periodontal treatment on systemic inflammatory mediators perio-CHD
Methods • Study type: parallel RCT
• Randomisation: not clearly stated
• Allocation concealment: not clearly stated
• Blinding: single-blinded (investigator)
Participants • Inclusion criteria:
* A) General/medical: 1) any race/ethnic group; 2) aged > 30 years; 3) male or female; 4) coronary
heart disease (CHD) case confirmed by CHD angiography; 5) CHD diagnosed > 3 months prior
to entry into study; 6) no acute or chronic systemic conditions (see exclusion criteria below);
7) no medications/medication history that can interfere with the study (see exclusion criteria
below); 8) non-smoker (= never smoked) or former smoker (= does not smoke now and has not
smoked at all for a minimum of the last 12 consecutive months); 9) able and willing to comply
with study procedures; 10) able and willing to be available for the duration of the study; 11)
able and willing to provide signed informed consent.
* B) Oral/periodontal: 1) dentate with at least 14 natural teeth, excluding third molars, which can
be evaluated periodontally; 2) baseline whole mouth BOP > 20% of sites; 3) periodontitis case:
periodontitis case defined as subject having ≥ 4 teeth with ≥ 1 site with PPD ≥ 4 mm and CAL
≥ 3 mm at same site; 4) no mechanical periodontal therapy in the last 6 months; 5) no acute
NCT01201746 
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oral diseases (mucosal lesions), oral infections, need for immediate dental/periodontal care
(e.g. NUG)
• Exclusion criteria:
* A) General/medical: 1) former smoker who does not smoke, but who has smoked 1 cigarette
(or equivalent, in form of water pipe, pipe, cigar) in the last 12 months; 2) females pregnant
or lactating; 3) systemic chronic conditions known to be associated with periodontitis or with
changes in systemic inflammation: diabetes, rheumatoid arthritis, rheumatic fever, SLE, ma-
lignancy, respiratory diseases, renal diseases, other (e.g. autoimmune diseases, fungal infec-
tions, immunological deficiencies, etc.); 4) systemic acute conditions known to affect systemic
markers of inflammation: acute bacterial infection, acute viral infection (common cold, in-
fluenza, sinusitis), orthopaedic trauma, surgery; 5) medications known to affect systemic in-
flammatory biomarker: statins, systemic steroids, non-steroidal anti-inflammatory drugs, im-
munosuppressants; 6) medications potentially affecting systemic inflammatory markers, if
therapy started less than 3 months prior to study, such as hormone replacement therapy, con-
traceptives; 7) systemic antibiotic therapy in the last 3 months.
* B) Oral/periodontal: 1) BOP in 20% of sites; 2) topical/local antibiotic or anti-inflammatory
therapy in last 6 months; 3) acute oral infections; 4) oral wounds, including recent (< 2 months)
extractions
• Total number of participants: 317
Interventions • Intervention group: SRP and oral hygiene instructions
• Control group: no treatment
• Follow-up: unclear
Outcomes Changes in hs-CRP (the time of recording is unclear)
Starting date July 2008
Contact information Mohammad Azhar, Punjab Institute of Cardiology, Pakistan




Trial name or title Scientific title. Periodontal therapy in coronary artery patients (PerioCardio)
Public title. Periodontal therapy in coronary artery patients (PerioCardio)
Methods • Study type: parallel RCT
• Randomisation: mentioned but the detail was not clear
• Allocation concealment: not clearly stated
• Blinding: single-blinded (outcomes assessor)
Participants • Inclusion criteria: 35 to 70 years old; coronary artery disease; more than 10 teeth; chronic peri-
odontitis, defined as 2 non-adjacent teeth with probing depth > 5 mm and periodontal attach-
ment loss > 4 mm
• Exclusion criteria: use of antibiotics in the last 6 months; periodontal therapy in the last 12 months
• Total number of participants: 100
Interventions • Intervention group: SRP under local anaesthesia + oral hygiene instruction and motivation
• Control group: 1 session of supra-gingival calculus removal
• Follow-up: 1 year
NCT01609725 
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Outcomes Changes of hs-CRP, HDL-C, LDL-C, and total cholesterol levels (3, 6 months, and 1 year after the
treatment)
Starting date January 2012





Trial name or title PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke
Methods • Study type: parallel RCT
• Randomisation: participants will be randomised using a 1:1 adaptive randomisation protocol to
aggressive periodontal therapy (scaling and root planing (SRP) + standard of care stroke preven-
tion strategies) versus standard dental care with community dental referral + standardised stroke
prevention.
• Allocation concealment: not clearly stated
• Blinding: not clearly stated
Participants • Inclusion criteria: at least 18 years of age (no upper limit); able to consent, follow an outpatient
protocol, and available by telephone; initial stroke not causing severe disability (modified Rankin
score ≤ 3) or TIA in the past 90 days; suitable for periodontal examination and treatment (≥ 5 teeth)
and a dental examination, with ≥ 2 interproximal sites with ≥ 4 mm of CAL
• Exclusion criteria: stroke due to intracranial haemorrhage, dissection, veno-occlusive disease,
drugs, trauma, or vasculitis; previous neurological impairment that would make detection of a
subsequent event difficult; comorbid conditions that may limit survival to less than a year; brain
CT or MRI that shows a lesion other than stroke as the cause of the syndrome; history of medical
conditions requiring antibiotic prophylaxis prior to dental exam (artificial cardiac valves, previous
inflammation of the heart or valves, complex heart conditions or other heart malformations since
birth, surgically constructed systemic pulmonary shunts, valvular dysfunctions, prolapse, hyper-
trophic cardiomyopathy, first two years of joint replacement, previous infections from artificial
joint, any chronic or radiation-induced condition leading to immunosuppression or haemophil-
ia); patients on oral anticoagulant therapy with a prothrombin time international normalized ra-
tio (PT-INR) greater than 3.5 (may be corrected and enrolled); pregnancy confirmed by urine preg-
nancy test in women of child-bearing potential (≤ 55 years age); known allergy or hypersensitivity
to local anaesthesia, or minocycline that cannot be medically managed; participation in another
RCT
• Total number of participants: 400
Interventions • Intensive dental treatment group: up to 5 sessions of full-mouth removal of subgingival dental
plaque by the use of scaling and root planning under local anaesthesia. Hopeless teeth extraction.
Administer Arestin locally into the periodontal pockets ≥ 6 mm
• Standard dental treatment: supragingival mechanical scaling and polishing
• All participants will be given instructions in basic oral hygiene and treated for stroke risk factors
in accordance to the current guidelines for secondary stroke prevention.
Outcomes • Primary outcomes: ischaemic stroke, TIA, myocardial infarction, cardiovascular death
• Primary outcomes were recorded at 3, 6, 9, and 12 months from randomisation
• Secondary outcomes: IMT, vascular cognitive impairment, BP, hs-CRP, haemoglobin A1c, fasting
lipids
• All of the secondary outcomes, except BP, were recorded at baseline and at 1-year follow-up visit.
The BP was recorded at baseline and at follow-up: 6 and 12 months from randomisation.
NCT02541032 
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Starting date December 2015
Contact information Kolby T Redd, Department of Neurology, School of Medicine, University of South Carolina, Colum-





Trial name or title Brief title. Comprehensive oral intervention in patients with AMI
Official title. A randomized control trial of comprehensive oral intervention in patients with acute
myocardial infarction: a pilot study
Methods • Study type: parallel RCT
• Randomisation: people who agreed to the study were randomly assigned to the intervention
group and control group at a 1:1 ratio
• Allocation concealment: not clearly stated
• Blinding: single; participating patients and dentists are not able to be blinded from information
about random allocation. However, in order to reduce the bias, the cardiologist who treats the
participant and prescribes the medicines performs an investigator-masked design that masks in-
formation about the treatment group.
Participants • Inclusion criteria: adults over 18 years of age; diagnosed with type 1 or 2 MI according to the Fourth
Universal Definition of Myocardial Infarction (2018) criteria; with baseline hs-CRP (high-sensitivity
C-reactive protein) elevated above 1.0 mg/dL
• Exclusion criteria: inability to provide informed consent; patients who are predicted to have low
compliance; those whose life expectancy is less than 3 months due to cardiovascular disease or
other reasons; those whose condition is considered to be too poor to perform dental treatment, or
who have a high risk of bleeding; those who need active dental treatment, such as extraction; pa-
tients suspected of having active infection; those who are taking long-term systemic antibiotics or
receiving immunosuppressive treatment; fully edentulous (except for fixed implant restorations);
less than 15 teeth and implants; if the last dental visit experience is less than 6 months ago; if pe-
riodontal treatment is not possible by the researcher
• Estimated enrolment: 68 participants
Interventions • Intervention group: post-myocardial infarction management (dual antiplatelet drug); basic pe-
riodontal examinations (panorama radiograph: full-mouth periapical radiograph); active dental
procedure (scaling and root planing)
• Control group: post-myocardial infarction management (dual antiplatelet drug); basic periodon-
tal examinations (panorama radiograph: full-mouth periapical radiograph)
• Follow-up: 1 year
Outcomes Changes in BP (3 months and 12 months after treatment), number of cardiovascular-related
deaths, unscheduled coronary revascularisation, stroke, unstable angina, recurrent MI (12 months
after treatment)
Starting date 5 July 2019
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Trial name or title Scientific title. Associations between periodontal disease and cardiovascular surrogate endpoints
following periodontal treatment in an adult Indigenous population with moderate/severe peri-
odontal disease
Public title. Associations between periodontal disease and cardiovascular surrogate endpoints in
an adult indigenous population
Methods • Study type: parallel RCT
• Randomisation: after screening for periodontal disease, those with moderate or severe periodon-
tal disease will be randomised on a 1:1 basis to either the treatment or control group. A comput-
er-generated permuted block randomisation sequence will be used, stratified by recruitment site
(Darwin/Palmerston, Katherine)
• Allocation concealment: not clearly stated
• Blinding: measurement of cardiovascular endpoints and statistical analysis will be blinded
Participants • Inclusion criteria: Indigenous persons aged > 25 years, who have lived in their current location
for more than 2 years, and who plan to live at their current location for the next 2 years, with
moderate/severe periodontal disease
• Exclusion criteria: those with history of rheumatic heart disease or other cardiac conditions re-
quiring antibiotic prophylaxis for prevention of subacute bacterial endocarditis, or with obvious
endodontic lesions, or other sources of oral infection
• Total number of participants: 266
Interventions • Intervention group: SRP
• Control group: no treatment
• Follow-up: 1 year
Outcomes hs-CRP, HDL-C, LDL-C, APO-A1, APO-B and total cholesterol (3 months and 1 year after the treat-
ment)
Starting date June 2010
Contact information Lisa M Jamieson, Australian Research Centre for Population Oral Health, School of Dentistry, Uni-
versity of Adelaide, Adelaide, Australia
Notes Registered (retrospectively)
Skilton 2011 
BOP = bleeding on probing; BP = blood pressure CAL = clinical attachment level; hs-CRP = high-sensitivity C-reactive protein; HDL = high-
density lipoprotein; LDL = low-density lipoprotein; PPD = probing pocket depth; RCT = randomised controlled trial; SLE = systemic lupus
erythematosus; SRP = scaling and root planing; TIA = transient ischaemic attack
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Primary prevention: SRP plus antibiotics versus supragingival scaling





Statistical method Effect size
1 All-cause death (12 months) 1   Peto Odds Ratio (Peto, Fixed,
95% CI)
Totals not selected
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Statistical method Effect size
2 All CVD-related death (12 months) 1   Peto Odds Ratio (Peto, Fixed,
95% CI)
Totals not selected
3 All cardiovascular events (12 months) 1   Peto Odds Ratio (Peto, Fixed,
95% CI)
Totals not selected





Analysis 1.1.   Comparison 1 Primary prevention: SRP plus antibiotics
versus supragingival scaling, Outcome 1 All-cause death (12 months).
Study or subgroup SRP + A + M SS Peto Odds Ratio Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI Peto, Fixed, 95% CI
Lopez 2012 1/82 0/83 7.48[0.15,376.98]
Favours SRP + A + M 1000.01 100.1 1 Favours SS
 
 
Analysis 1.2.   Comparison 1 Primary prevention: SRP plus antibiotics
versus supragingival scaling, Outcome 2 All CVD-related death (12 months).
Study or subgroup SRP+A+M SS Peto Odds Ratio Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI Peto, Fixed, 95% CI
Lopez 2012 1/82 0/83 7.48[0.15,376.98]
Favours SRP+A+M 1000.01 100.1 1 Favours SS
 
 
Analysis 1.3.   Comparison 1 Primary prevention: SRP plus antibiotics versus
supragingival scaling, Outcome 3 All cardiovascular events (12 months).
Study or subgroup SRP+A+M SS Peto Odds Ratio Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI Peto, Fixed, 95% CI
Lopez 2012 4/82 0/83 7.77[1.07,56.14]
Favours SRP+A+M 1000.01 100.1 1 Favours SS
 
 
Analysis 1.4.   Comparison 1 Primary prevention: SRP plus antibiotics
versus supragingival scaling, Outcome 4 Adverse events (12 months).
Study or subgroup SRP+A+M SS Peto Odds Ratio Peto Odds Ratio
  n/N n/N Peto, Fixed, 95% CI Peto, Fixed, 95% CI
Lopez 2012 0/82 1/83 0.14[0,6.9]
Favours SRP+A+M 1000.01 100.1 1 Favours SS
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A D D I T I O N A L   T A B L E S
 
Journal name By ZD Shi, et
al
By CJ Li, et al By CJ Li and ZK Lv By CJ Li,
et al
Chinese Journal of Stomatology 1953 to Dec
2000
Jan 2001 to Dec 2009 Jan 2010 to May 2011  
Stomatology 1981 to Dec
2000
Jan 2001 to Dec 2009 Jan 2010 to May 2011  
West China Journal of Stomatology 1983 to Dec
2000
Jan 2001 to Dec 2009 Jan 2010 to May 2011  
Journal of Practical Stomatology 1985 to Dec
2000
Jan 2001 to Dec 2009 Jan 2010 to May 2011  
Journal of Clinical Stomatology 1985 to Dec
2000
Jan 2001 to Dec 2009 Jan 2010 to May 2011  
Journal of Comprehensive Stomatology 1985 to Dec
2000
Jan 2001 to Dec 2009 Jan 2010 to May 2011  
Journal of Modern Stomatology 1987 to Dec
2000
Jan 2001 to Dec 2009 Jan 2010 to May 2011  
Chinese Journal of Conservative Dentistry 1991 to Dec
2000
Jan 2001 to Dec 2009 Jan 2010 to May 2011  
Journal of Maxillofacial Surgery 1991 to Dec
2000
Jan 2001 to Dec 2009 Jan 2010 to May 2011  
Shanghai Journal of Stomatology 1992 to Dec
2000
Jan 2001 to Dec 2009 Jan 2010 to May 2011  
Chinese Journal of Dental Material and Devices 1992 to Dec
2000
Jan 2001 to Dec 2009 Jan 2010 to May 2011  
Beijing Journal of Stomatology 1993 to Dec
2000
Jan 2001 to Dec 2009 Jan 2010 to May 2011  




Jan 2001 to Dec 2009 Jan 2010 to May 2011  
Chinese Journal of Orthodontics 1994 to Dec
2000
Jan 2001 to Dec 2009 Jan 2010 to May 2011  
Chinese Journal of Implantology 1996 to Dec
2000
Jan 2001 to Dec 2009 Jan 2010 to May 2011  
Journal of International Stomatology   Jan 2001 to Dec 2009 1974 to Dec 2000, Jan 2010 to
May 2011
 
Table 1.   Stomatology journals handsearched 
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Chinese Journal of Prosthodontics   Jan 2001 to Dec 2009 1999 to Dec 2000, Jan 2010 to
May 2011
 
China Journal of Oral and Maxillofacial
Surgery
  2003 to Dec 2009 Jan 2010 to May 2011  
Chinese Journal of Geriatric Dentistry   2002 to Dec 2009 Jan 2010 to May 2011  
International Journal of Oral Science     2009 to May 2011 June 2011
to March
2019
International Journal of Periodontics &
Restorative Dentistry
    1981 to May 2011 June 2011
to March
2019
Journal of Clinical Periodontology     1974 to May 2011 June 2011
to March
2019
Journal of Periodontal Research     1966 to May 2011 June 2011
to March
2019
Journal of Periodontology     1949 to May 2011 June 2011
to March
2019
Periodontology 2000     1993 to May 2011 June 2011
to March
2019
Table 1.   Stomatology journals handsearched  (Continued)
 
 
Journal name By CJ Li and ZK Lv
Journal of Cardiovascular and Pulmonary Diseases 1982 to May 2011
Chinese Journal of Cardiology 1973 to May 2011
International Journal of Cerebrovascular Diseases 1993 to May 2011
Prevention and Treatment of Cardio-Cerebral-Vascular Disease 2001 to May 2011
Chinese Journal of Cerebrovascular Diseases 2004 to May 2011
Chinese Journal of Geriatric Heart Brain and Vessel Diseases 1999 to May 2011
Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease 2003 to May 2011
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease  1993 to May 2011
Circulation 1950 to May 2011
European Heart Journal 1980 to May 2011
Table 2.   Cardiovascular disease journals handsearched 
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Cardiovascular Research 1967 to May 2011
Circulation Research 1953 to May 2011
Cardiology 1937 to May 2011
Arteriosclerosis, Thrombosis, and Vascular Biology 1981 to May 2011
American Journal of Cardiology 1958 to May 2011
Table 2.   Cardiovascular disease journals handsearched  (Continued)
 
 
A P P E N D I C E S
Appendix 1. Cochrane Oral Health's Trials Register search strategy
From July 2013, searches of the Cochrane Oral Health Group's Trials Register were undertaken using the Cochrane Register of Studies and
the search strategy below:
#1 ((cardiovascular or myocardial or heart* or coronar* or "artery disease*" or angina or "transient ischaemic attack*" or atherosclerosis
or arteriosclerosis or "peripheral arterial disease*" or cerebrovascular or stroke* or ischemia or "intercranial hemorrhage" or "intercranial
haemorrhage" or thrombosis or thromboses or aneurysm* or embolism* or DVT):ti,ab) AND (INREGISTER)
#2 ((periodont* or gingivitis or gingiva* or paradont*):ti,ab) AND (INREGISTER)
#3 (#1 and #2) AND (INREGISTER)
Previous searches were undertaken using the Procite soNware and the search strategy below:
((cardiovascular or myocardial or heart* or coronar* or "artery disease*" or angina or "transient ischaemic attack*" or atherosclerosis or
arteriosclerosis or "peripheral arterial disease*" or cerebrovascular or stroke* or ischemia or "intercranial hemorrhage" or "intercranial
haemorrhage" or thrombosis or thromboses or aneurysm* or embolism* or DVT) AND (periodont* or gingivitis or gingiva* or paradont*))
Cochrane Oral Health’s Trials Register is available via the Cochrane Register of Studies. For information on how the register is compiled,
see https://oralhealth.cochrane.org/trials
Appendix 2. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
#1. Exp CARDIOVASCULAR DISEASES
#2. (myocardial or heart*) NEAR infarc*
#3. heart NEAR (disease* or attack*)
#4. (coronary NEAR (artery disease* or syndrome*))
#5. (angina pectoris OR "transient ischaemic attack*")
#6. exp ATHEROSCLEROSIS
#7. (atherosclerosis OR arteriosclerosis)
#8. "peripheral arterial disease"
#9. exp CEREBROVASCULAR DISORDERS
#10. (stroke* or (ischemia NEAR brain*) OR (infarc* NEAR brain*) OR "intercranial haemorrhage*" or "intercranial hemorrhage*")
#11. exp THROMBOSIS
#12. (thrombosis or occlusion* or thromboses or aneurysm* or embolism*)
#13. (DVT):ti,ab
#14. ("atheromatous plaque" or atheromata*)
#15. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14
#16. exp PERIODONTAL DISEASES
#17. periodont*
#18. (gingivitis or gingival*)
#19. paradont*
#20. #16 OR #17 OR #18 OR #19
#21. exp PREVENTIVE DENTISTRY
#22. Dental Care for Chronically Ill
#23. exp PERIODONTICS
#24. (scal* NEAR polish*)
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#25. (root* NEAR plan*)
#26. (tooth NEAR scal*) OR (teeth NEAR scal*) OR (dental NEAR scal*)
#27. (oral AND dental AND prophylaxis)
#28. (gingivectomy OR gingivoplasty OR "subgingival curretage" OR subgingival curettage" OR "guided tissue regeneration")
#29. Surgical flaps
#30. "surgical flap*"
#31. ((#29 OR #30) AND periodont*)
#32. (periodont* NEAR (therap* OR treat* OR surger*))
#33. Oral Health
#34. exp ORAL HYGIENE
#35. (mouthrinse* OR mouth-rinse* OR "mouth rinse*" OR mouthwash* OR mouth-wash* OR "mouth wash*" OR toothbrush* OR "tooth
brush*" OR tooth-brush* OR floss*)
#36. exp DENTIFRICES
#37. (dentifrice* OR toothpaste* OR tooth-paste* OR "tooth paste*")
#38. Chlorhexidine
#39. (chlorhexidine OR eludril OR chlorohex* or corsodyl)
#40. exp ANTI-BACTERIAL AGENTS
#41. (antibiotic* or anti-biotic* or antibacterial* or anti-bacterial*)
#42. exp TETRACYCLINES
#43. (tetracycline* OR doxycycline* OR minocycline* OR roxithromycin* OR moxifloxacin* OR ciprofloxacin* OR metronidazole*)
#44. (Periostat OR Atridox OR Elyzol OR PerioChip OR Arestin OR Actisite)
#45. #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR
#40 OR 41 OR #42 OR #43 OR #44
#46. #15 AND #20 AND #45
Appendix 3. MEDLINE Ovid search strategy
1. exp Cardiovascular diseases/
2. ((myocardial or heart$) adj5 infarc$).mp.
3. (heart adj6 (disease$ or attack$)).mp.
4. (coronary adj6 (disease$ or syndrome$)).mp.
5. (angina or "transient ischaemic attack$").mp.
6. exp Atherosclerosis/
7. (atherosclerosis or arteriosclerosis).mp.
8. "peripheral arterial disease".mp.
9. exp Cerebrovascular Disorders/
10. (stroke$ or (ischemia adj3 brain$) or (infarc$ adj3 brain$) or "intercranial haemorrhage$" or "intercranial hemorrhage$").mp.
11. exp Thrombosis/
12. (thrombosis or occulsion$ or thromboses or aneurysm$ or embolism$).mp.
13. DVT.ti,ab.
14. ("atheromatous plaque" or atheromata$).mp.
15. or/1-14
16. exp Periodontal Diseases/
17. periodont$.mp.
18. (gingivitis or gingiva$).mp.
19. paradont$.mp.
20. or/16-19
21. exp Preventive Dentistry/
22. Dental Care for Chronically Ill/
23. exp Periodontics/
24. (scal$ adj4 polish$).mp.
25. (root$ adj4 plan$).mp.
26. ((tooth adj6 scal$) or (teeth adj6 scal$) or (dental adj6 scal$)).mp.
27. (oral and dental and prophylaxis).mp.
28. (gingivectomy or gingivoplasty or "subgingival curretage" or "guided tissue regeneration").mp.
29. Surgical flaps/
30. "surgical flap$".mp.
31. ((29 or 30) and periodont$).mp.
32. (periodont$ adj3 (therap$ or treat$ or surger$)).mp.
33. Oral Health/
34. exp Oral Hygiene/
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis (Review)









Cochrane Database of Systematic Reviews
35. (mouthrinse$ or mouth-rinse$ or "mouth rinse$" or mouthwash$ or mouth-wash$ or "mouth wash$" or toothbrush$ or "tooth brush
$" or tooth-brush$ or floss$).mp.
36. exp Dentifrices/
37. (dentifrice$ or toothpaste$ or tooth-paste$ or "tooth paste$").mp. [mp=title, original title, abstract, name of substance word, subject
heading word, unique identifier]
38. Chlorhexidine/
39. (chlorhexidine or eludril or chlorohex$ or corsodyl).mp.
40. exp Anti-bacterial agents/
41. (antibiotic$ or anti-biotic$ or antibacterial$ or anti-bacterial$).mp.
42. exp Tetracyclines/
43. (tetracycline$ or doxycycline$ or minocycline$ or roxithromycin$ or moxifloxacin$ or ciprofloxacin$ or metronidazole$).mp.
44. (Periostat or Atridox or Elyzol or PerioChip or Arestin or Actisite).mp.
45. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44
46. 15 and 20 and 45
This subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in MEDLINE:
sensitivity-maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of The Cochrane Handbook for
Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011] (Lefebvre 2011).
1. randomized controlled trial.pt.








10. exp animals/ not humans.sh.
11. 9 not 10
Appendix 4. Embase Ovid search strategy
1. exp Cardiovascular diseases/
2. ((myocardial or heart$) adj5 infarc$).mp.
3. (heart adj6 (disease$ or attack$)).mp.
4. (coronary adj6 (artery disease$ or heart muscle ischemia)).mp.
5. (angina pectoris or "transient ischaemic attack$").mp.
6. exp Atherosclerosis/
7. (atherosclerosis or arteriosclerosis).mp.
8. "peripheral arterial disease".mp.
9. exp Cerebrovascular Disorders/
10. (stroke$ or (ischemia adj3 brain$) or (infarc$ adj3 brain$) or "inter cranial haemorrhage$" or "inter cranial hemorrhage$").mp.
11. exp Thrombosis/
12. (thrombosis or occlusion$ or "occlusive cerebrovascular disease" or aneurysm$ or embolism$).mp.
13. DVT.ti,ab.
14. ("atherosclerotic plaque" or atheroma$).mp.
15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16. exp Periodontal Diseases/
17. periodont$.mp.
18. (gingivitis or gingiva$).mp.
19. paradont$.mp.
20. 16 or 17 or 18 or 19
21. exp Preventive Dentistry/
22. Dental Care for Chronically Ill/
23. exp Periodontics/
24. (scal$ adj4 polish$).mp.
25. (root$ adj4 plan$).mp.
26. ((tooth adj6 scal$) or (teeth adj6 scal$) or (dental adj6 scal$)).mp.
27. (oral and dental and prophylaxis).mp.
28. (gingivectomy or gingivoplasty or "subgingival curretage" or "subgingival curettage" or "guided tissue regeneration").mp.
29. Surgical flaps/
30. "surgical flap$".mp.
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31. (29 or 30) and periodont$.mp.
32. (periodont$ adj3 (therap$ or treat$ or surger$)).mp.
33. Oral Health/
34. exp Oral Hygiene/
35. (mouthrinse$ or mouth-rinse$ or "mouth rinse$" or mouthwash$ or mouth-wash$ or "mouth wash$" or toothbrush$ or "tooth brush
$" or tooth-brush$ or floss$).mp.
36. exp Dentifrices/
37. (dentifrice$ or toothpaste$ or tooth-paste$ or "tooth paste$").mp.
38. Chlorhexidine/
39. (chlorhexidine or eludril or chlorohex$ or corsodyl).mp.
40. exp Anti-bacterial agents/
41. (antibiotic$ or anti-biotic$ or antibacterial$ or anti-bacterial$).mp.
42. exp Tetracyclines/
43. (tetracycline$ or doxycycline$ or minocycline$ or roxithromycin$ or moxifloxacin$ or ciprofloxacin$ or metronidazole$).mp.
44. (Periostat or Atridox or Elyzol or PerioChip or Arestin or Actisite).mp.
45. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39. or 40 or 41 or 42 or 43 or 44
46. 15 and 20 and 45
The above subject search was linked to adapted version of the Cochrane Embase Project filter for identifying RCTs in Embase Ovid (see
http://www.cochranelibrary.com/help/central-creation-details.html for information):
1. Randomized controlled trial/





7. (compare or compared or comparison).ti.
8. ((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing or comparison)).ab.
9. (open adj label).ti,ab.
10. ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab.
11. double blind procedure/
12. parallel group$1.ti,ab.
13. (crossover or cross over).ti,ab.
14. ((assign$ or match or matched or allocation) adj5 (alternate or group$1 or intervention$1 or patient$1 or subject$1 or participant
$1)).ti,ab.
15. (assigned or allocated).ti,ab.
16. (controlled adj7 (study or design or trial)).ti,ab.
17. (volunteer or volunteers).ti,ab.
18. trial.ti.
19. or/1-18
20. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
21. 19 not 20
Appendix 5. CINAHL EBSCO search strategy
S1 MH Cardiovascular diseases
S2 (myocardial or (heart* N5 infarc*))
S3 (heart N6 disease* or attack*)
S4 (coronary N6 disease* or syndrome*)
S5 (angina or "transient ischaemic attack*")
S6 MH Atherosclerosis
S7 (atherosclerosis or arteriosclerosis)
S8 "peripheral arterial disease"
S9 MH Cerebrovascular Disorders
S10 (stroke* or (ischemia N3 brain*) or (infarc* N3 brain*) or intracranial haemorrhage* or intracranial hemorrhage*)
S11 MH Thrombosis
S12 (thrombosis or occlusion* or thromboses or aneurysm* or embolism*)
S13 TI DVT or AB DVT
S14 ("atheromatous plaque" or ¡°atherosclerotic plaque¡± or atheromata*)
S15 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14
S16 MH Periodontal Diseases
S17 periodont*
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S18 (gingivitis or gingival*)
S19 paradont*
S20 S16 or S17 S18 or S19
S21 MH Preventive Dentistry
S22 Dental Care for Chronically Ill
S23 MH Periodontics
S24 (scal* N4 polish*)
S25 (root* N4 plan*)
S26 (tooth N6 scal*) or (teeth N6 scal*) or (dental N6 scal*)
S27 oral and dental and prophylaxis
S28 (gingivectomy or gingivoplasty or subgingival curettage* or guided tissue regeneration)
S29 Surgical flaps
S30 "surgical flap*"
S31 ((S29 or S30) and periodont*)
S32 (periodont* N3 therap* or treat* or surger*)
S33 Oral Health
S34 MH Oral Hygiene
S35 (mouthrinse* or mouth-rinse* or "mouth rinse*" or mouthwash* or mouth-wash* or "mouth wash*" or toothbrush* or "tooth brush*"
or tooth-brush* or floss*)
S36 MH Dentifrices
S37 (dentifrice* or toothpaste* or tooth-paste* or "tooth paste*")
S38 Chlorhexidine
S39 (chlorhexidine or eludril or chlorohex* or corsodyl)
S40 Anti bacterial agents
S41 (antibiotic* or anti-biotic* or antibacterial* or anti-bacterial*)
S42 Tetracyclines
S43 (tetracycline* or doxycycline* or minocycline* or roxithromycin* or moxifloxacin* or ciprofloxacin* or metronidazole*)
S44 (Periostat or Atridox or Elyzol or PerioChip or Arestin or Actisite)
S45 S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 or
S42 or S43 or S44
S46 S15 and S20 and S45
The above subject search was linked to Cochrane Oral Health's filter for CINAHL EBSCO:
S1 MH Random Assignment or MH Single-blind Studies or MH Double-blind Studies or MH Triple-blind Studies or MH Crossover design or
MH Factorial Design 
S2 TI ("multicentre study" or "multicenter study" or "multi-centre study" or "multi-center study") or AB ("multicentre study" or "multicenter
study" or "multi-centre study" or "multi-center study") or SU ("multicentre study" or "multicenter study" or "multi-centre study" or "multi-
center study")
S3 TI random* or AB random* 
S4 AB "latin square" or TI "latin square"
S5 TI (crossover or cross-over) or AB (crossover or cross-over) or SU (crossover or cross-over) 
S6 MH Placebos 
S7 AB (singl* or doubl* or trebl* or tripl*) or TI (singl* or doubl* or trebl* or tripl*)
S8 TI blind* or AB mask* or AB blind* or TI mask* 
S9 S7 and S8
S10 TI Placebo* or AB Placebo* or SU Placebo* 
S11 MH Clinical Trials
S12 TI (Clinical AND Trial) or AB (Clinical AND Trial) or SU (Clinical AND Trial)
S13 S1 or S2 or S3 or S4 or S5 or S6 or S9 or S10 or S11 or S12 
Appendix 6. OpenGrey search strategy
(periodont* or paradont*) AND cardiovascular
(periodont* or paradont*) AND heart*
(periodont* or paradont*) AND stroke*
(periodont* or paradont*) AND coronar*




Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis (Review)









Cochrane Database of Systematic Reviews
coronary AND periodontitis
Appendix 8. WHO International Clinical Trials Registry Platform search strategy
cardiovascular AND periodont*
stroke AND periodont*
"heart disease" AND periodont*
coronar* AND periodont*




4. #1 and #2 and #3 -限定:-
Appendix 10. China National Knowledge Infrastructure search strategy
( ( ( 摘要=⼼⾎管 或者 摘要=⼼脏 ) 并且 主题=⽛周 ) 并且 摘要=随机 ) (精确匹配),专辑导航：全部; 数据库：⽂献 跨库检索
Appendix 11. VIP search strategy
题名或关键词=⽛周 并且 题名或关键词=⼼脏 并且 ⽂摘=随机
Appendix 12. Sciencepaper Online search strategy
题⽬=⽛周 与 （题⽬=⼼脏 或 题⽬=⼼⾎管） 与 摘要=随机
W H A T ' S   N E W
 
Date Event Description
28 December 2019 New citation required and conclusions
have changed
One new study included, which provides very low-certainty evi-
dence relating to primary prevention.
17 September 2019 New search has been performed Search updated. One new study identified for inclusion and one
awaiting classification. Title changed. Author order on byline
changed and new authors added.
 
H I S T O R Y
Protocol first published: Issue 7, 2011
Review first published: Issue 8, 2014
 
Date Event Description
26 September 2017 New citation required but conclusions
have not changed
Conclusions remain the same as we did not identify any new
studies for inclusion.
23 September 2017 New search has been performed Search updated. No new studies included. New information
added in background and discussion.
 
C O N T R I B U T I O N S   O F   A U T H O R S
• Chunjie Li and Zongkai Lv proposed this clinical question, registered the title with Cochrane Oral Health.
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• DraNing and revising of the protocol: Chunjie Li, Zongkai Lv, Ye Zhu, and Yafei Wu
• Searching of Chinese databases: Wei Liu
• Study identification: Chunjie Li and Wei Liu
• Data extraction and 'Risk of bias' assessment: Wei Liu and Yubin Cao
• Data management and data analysis: Wei Liu and Yubin Cao
• Data interpreting: Yafei Wu, Ye Zhu, and Li Dong
• DraNing/updating the review: Wei Liu and Yubin Cao
• Revising the updated review: Chunjie Li, Zongkai Lv, Ye Zhu, Yafei Wu, Li Dong, and Zipporah Iheozor-Ejiofor
D E C L A R A T I O N S   O F   I N T E R E S T
• Chunjie Li was supported by the 2011 Aubrey Sheiham Public Health & Primary Care Scholarship, and finished the systematic review at
the UK Cochrane Centre. We declare that the scholarship had no impact on the review content.
• Chunjie Li was also supported by 2018 Sichuan University-Luzhou Municipal Government Strategic Cooperation Research during the
updating of the review. We declare that the research funding only provided financial support, without influencing any procedure and
result of the review.
• Wei Lui, Yubin Cao, Li Dong, Ye Zhu, Yafei Wu, Zongkai Lv: none known
• Zipporah Iheozor-Ejiofor: none known. Zipporah is an editor with Cochrane Oral Health
S O U R C E S   O F   S U P P O R T
Internal sources
• West China College of Stomatology, Sichuan University, China.
• Chinese Cochrane Center, China.
• Aubrey Sheiham Public Health & Primary Care Scholarship 2011, UK.
• School of Dentistry at The University of Manchester, Manchester Academic Health Sciences Centre (MAHSC) and the NIHR Manchester
Biomedical Research Centre, UK.
• 2018 Sichuan University-Luzhou Municipal Government Strategic Cooperation Research, China.
(2018CDLZ-12)
External sources
• Cochrane Oral Health Global Alliance, UK.
The production of Cochrane Oral Health reviews has been supported financially by our Global Alliance since 2011 (ohg.cochrane.org/
partnerships-alliances). Recent contributors have been: British Association for the Study of Community Dentistry, UK; British Society
of Paediatric Dentistry, UK; the Canadian Dental Hygienists Association, Canada; Centre for Dental Education and Research at All
India Institute of Medical Sciences, India; National Center for Dental Hygiene Research & Practice, USA; New York University College of
Dentistry, USA; NHS Education for Scotland, UK; Swiss Society for Endondontology, Switzerland.
• UK Cochrane Centre, UK.
• National Institute for Health Research (NIHR), UK.
This project was supported by the NIHR, via Cochrane Infrastructure funding to Cochrane Oral Health. The views and opinions expressed
therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the
Department of Health.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
• We modified the title from 'management' to 'primary and secondary prevention' and removed 'chronic'.
• We removed quasi-randomised controlled trials from the inclusion criteria because of the risk of bias.
• We modified the inclusion criteria in terms of participant disease – we changed depth of the periodontal pockets from 5 mm to 4 mm.
This decision was based on clinical expert advice to shiN focus from the severity of periodontitis to any clinical diagnosis of periodontitis.
• We added the following exclusion criteria that were erroneously omitted from the protocol: patients with severe systemic diseases other
than cardiovascular disease (CVD), who are pregnant, lactating or unable to return for follow-up and studies not focusing on primary
or secondary prevention of CVD.
• We added follow-up time of one year or longer to the Types of studies, as suggested by Cochrane Oral Health.
• We added secondary outcome heart function parameters (such as ejection fraction, etc.), in line with the aims of this review.
• The Cochrane Heart Group's Trials Register was not searched, as all trials in the register were also available in CENTRAL.
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Cochrane Database of Systematic Reviews
• The US National Institutes of Health Trials Register was added to the search, in accordance with the new standards for the conduct of
Cochrane Reviews (MECIR version 2.3).
• The description of the seven domains used for 'Risk of bias' assessment changed (as the Cochrane Handbook for Systematic Reviews of
Interventions evolved from version 5.0 to 5.1), but the essence stayed the same.
• In the section 'Assessment of risk of bias', we deleted the section that stated we excluded the third domain from the overall assessment.
Although it is diHicult to blind the participants for periodontal therapy, a study without blinding of participants is at high risk of bias.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Cardiovascular Diseases  [etiology]  [*prevention & control];  Chronic Periodontitis  [complications]  [*therapy];  Coronary Disease
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